Northeastern University School of Law
- toggleGerald Quirk Joins Choate
Gerald Quirk, former Vice President of Corporate Affairs and General Counsel at Nasdaq-listed Infinity Pharmaceuticals, has joined the firm as co-chair of the Life Sciences Group. Read more...
“as a former in-house counsel, [he] has keen insight into the business interests of clients"
IAM Patent 1000
Gerald Quirk, co-chair of the Life Sciences Group, delivers sophisticated counsel that advances the legal and business interests of public and private life sciences companies, informed by nearly 15 years of in-house industry experience. Mr. Quirk is a corporate life sciences and IP transactional attorney who provides proactive and pragmatic advice to executive management and boards of directors, uniting legal expertise with business savvy. He is named in The Legal 500 and as a World’s Leading Patent Practitioner by IAM Patent 1000.
Technology Transactions & Licensing: represents life sciences companies in structuring and negotiating strategic transactions, including joint ventures, collaborations and intellectual property licenses. Experienced in representing both licensors and licensees in transactions spanning the research, development and commercialization of biopharmaceutical products, diagnostic products and medical devices.
Corporate: advises life sciences clients on various corporate matters, including contracts associated with the research, development, manufacture and commercialization of biopharmaceutical products, diagnostic products and medical devices, securities law compliance, and financing and M&A transactions.
Corporate Governance: advises boards of directors and senior management teams on sensitive corporate governance and compliance issues.
Vice President, Corporate Affairs and General Counsel, Secretary, Infinity Pharmaceuticals, Inc.: key member of executive leadership team responsible for the company’s legal, finance and corporate communications/investor relations departments. Mr. Quirk structured and negotiated key strategic alliances and license arrangements to grow the company’s product portfolio, obtain non-dilutive financing and retain key commercialization rights. His responsibilities also included securities law compliance, close collaboration with the company’s Board of Directors and Board committees on corporate governance matters, development of scalable compliance policies and operating guidelines, and management of crisis situations. Mr. Quirk was also responsible for the significant growth of the company’s patent portfolio and development of its patent and licensing strategy.
Managing Corporate Counsel, Assistant Secretary, Genzyme Corporation: managed all corporate legal functions for four global business units and served as part of the senior operational management team for these businesses. Mr. Quirk’s responsibilities included management of all M&A, IP licensing, supply and distribution, and other commercial transactions for these business units, including performing due diligence investigations, drafting and negotiating contracts, and leading post-merger integration activities.
- Represented a global specialty biopharmaceutical company in a collaboration to develop first-in-class small molecule therapies for lysosomal storage disorders.
- Represented a premier antibody discovery and optimization platform company in a product development collaboration with leading Chinese antibody therapeutics and manufacturing company.
- Counsel to a leader in allergy immunotherapies in association with an exclusive license from an international biopharmaceutical company for the US commercialization of an oral grass allergy immunotherapy product and activities in support of commercial launch.
- Represented a rapidly-growing developer of peptide-based therapeutics in obtaining exclusive rights to a novel technology platform enabling the oral formulation of a peptide that is in multiple clinical trials in various hematologic conditions.
- Counsel to several early-stage companies in accessing technology rights from leading academic institutions in connection with company formations.
- Engaged as outside securities counsel to a growing oncology therapeutics company, managing public and private capital-raising activities.
- Structured and negotiated significant business transactions as in-house counsel, including a multi-product strategic alliance that provided over $300 million in non-dilutive capital, a $1 billion acquisition facilitating forward integration into new disease areas, an $88 million confidentially-marketed public stock offering, and numerous collaborations, joint ventures and licenses to support worldwide development and commercialization of small molecules, biologics and medical devices across multiple disease indications.
Publications and Presentations
- “Practical Tips for Canadian Companies Launching in the US Market,” speaker, Canadian Entrepreneurs in New England's 48hrs in the Hub, October 2014.
- “Navigating the Trade Secret Minefield in the US,” speaker, Wragge Lawrence Graham & Co. Life Sciences Seminar, October 2014.
- “Termination or Restructuring of a Collaboration,” moderator, Licensing Executive Society’s 50th Annual Meeting, October 2014.
- "Small Business and Intellectual Property," presenter, National Institute of Allergy and Infectious Diseases' Small Business Workshop, September 2014.
- “Life Sciences Should Brace for Florida Rad Source Ruling,” co-author, Life Sciences Law360, March 2014.
- "Creating Value for Novel Platform Technology Engines: Ratchet up Your Negotiating Skills with Insights into Competitive Platform Deals" co-moderator, The Licensing Executives Society Annual Meeting, September 2013.
- “The Life Sciences Industry: Investing in the Perfect Hedge,” co-moderator, Canadian Venture Capital & Private Equity Association Conference, Banff, May 2013.
- “Structuring Effective Life Science Collaborations,” speaker, Boston Bar Association, Boston, April 2013.
- “Successful Life Science Collaborations Require Flexibility,” co-author, Life Sciences Law360, February 2013.
- “Can Small Life Sciences Companies Survive in the 21st Century?” moderator, New England-Israel Business Council’s Life Sciences Summit, Waltham, MA, November 2012.
- “Science, Industry, Collaboration and Innovation in Massachusetts,” speaker, Massachusetts Biotechnology Council 2009 Annual Meeting, Boston, April 2009.
- “Licenses and Other Contractual Agreements – An Industry Perspective,” speaker, Association of University Technology Managers 2009 Annual Meeting, Orlando, February 2009.
- “Essential Components of Life Sciences Due Diligence,” speaker, American Conference Institute – Life Sciences Mergers & Acquisitions, New York, March 2008.
- “Licensing Relationships,” speaker, Suffolk University Law School – Licensing: Seizing Opportunities and Mitigating Risks, Boston, November 2007.
- “Recent Developments Affecting Licensing,” speaker, Boston Bar Association, Intellectual Property Year in Review, Boston, January 2007.
- “Effective Decision-Making and Dispute Resolution in the Biotech Alliance,” speaker, Licensing Executives Society, Boston Chapter Meeting, Boston, October 2006.
- “Biotech/Pharma Research & Development: Role of Licensing and Mergers & Acquisitions,” speaker, US Federal Trade Commission Roundtable on the Economics of the Pharmaceutical Industry, Washington, DC, October 2006.
- “IP Due Diligence: Ownership, Inventorship & Loss of Licensed Rights,” speaker, American Conference Institute – Life Sciences IP Due Diligence, New York, January 2006.
Professional and Community Involvement
Mr. Quirk is a mentor to the Blavatnik Fellows for Life Science Entrepreneurship at Harvard Business School and a former member of the Executive Committee of BIO’s General Counsels Committee. Outside of the office, Mr. Quirk is a member of the Lincoln–Sudbury Regional School Committee and an enthusiastic youth soccer coach.